Tagomics Partners with Agilent Technologies to Revolutionize Multiomic Biomarker Discovery

Bio-Techne Partners with Leader Life Sciences to Expand in the GCC Region

Owkin and Proscia Partner to Revolutionize MSI Testing for Colorectal Cancer with AI-Powered Solutions

Telix Expands Theranostic Pipeline with FAP-Targeting Radiopharmaceuticals

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson’s Disease Biomarker Discovery

Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

Home
/
update
/
details

Owkin and Proscia Partner to Revolutionize MSI Testing for Colorectal Cancer with AI-Powered Solutions

NextEdge Admin

20 Nov 2024

2 min 16 sec

AI-driven biotech,MSI testing,colorectal cancer,Proscia

Owkin, a pioneer in AI-driven biotech, and Proscia, a leader in AI-enabled pathology, have partnered to enhance MSI testing for colorectal cancer (CRC), the world’s second most deadly cancer. This collaboration aims to integrate Owkin’s MSIntuit CRC v2 with Proscia’s Concentriq platform, streamlining MSI screening and expanding its accessibility through Proscia’s precision medicine AI portfolio.

MSI, a genomic biomarker found in 10–12% of CRC cases, is crucial for treatment decisions, as MSI-positive patients benefit from immune checkpoint inhibitors but not chemotherapy in stage II. Current testing methods, including IHC staining, PCR, and NGS, can be costly, labor-intensive, and tissue-consuming. MSIntuit CRC v2, with a sensitivity of 95% comparable to standard techniques, offers a more efficient alternative by ruling out nearly half of patients from unnecessary MSI testing.

Dr. Thomas Clozel, CEO of Owkin, emphasized the collaboration's potential to alleviate burdens on laboratories while improving patient outcomes. David West, CEO of Proscia, highlighted the partnership’s role in advancing AI’s impact on pathology and precision medicine.

Owkin joins Proscia’s Ready partner alliance, supporting the integration and scaling of AI-powered digital pathology. Together, they aim to accelerate the adoption of innovative AI solutions for diagnosis and drug discovery, benefiting laboratories and patients globally.

MSIntuit CRC is under development in the US and Europe, with regulatory submissions pending. Both companies remain committed to harnessing AI to transform medical research, diagnostics, and treatment.